Ginkgo Bioworks to go public in SPAC deal worth over $1.6B

By The Science Advisory Board staff writers

September 15, 2021 -- Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC).

The deal was approved by Soaring Eagle's shareholders on September 14. Subject to customary closing conditions, Soaring Eagle anticipates that the deal with Gingko will close on September 16. Following closing, Soaring Eagle will change its name to Ginkgo Bioworks Holdings.

The combined company's shares of class A common stock and public warrants are expected to begin trading on the New York Stock Exchange on September 17, 2021, under the ticker symbols DNA and DNA.WS, respectively.

Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies
Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...
Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...

Copyright © 2021 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter